[Prolonged intravenous and intra-arterial administration of large doses of Raubasine in peripheral arterial diseases].
D000328:Adult; D000368:Aged; D000404:Ajmaline / Q000008:administration & dosage*; D000783:Aneurysm / Q000188:drug therapy; D001161:Arteriosclerosis / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000188:drug therapy; D004617:Embolism / Q000188:drug therapy; D005260:Female; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000188:drug therapy; D012110:Reserpine / Q000008:administration & dosage*; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy; D013997:Time Factors; D014652:Vascular Diseases / Q000188:drug therapy*; D014655:Vascular Resistance / Q000187:drug effects
D000404:Ajmaline; D012110:Reserpine
La somministrazione protratta endovenosa ed endoarteriosa di alte dosi di Raubasina nelle arteriopatie periferiche.